Johnson & Johnson Acquires Halda Therapeutics for $3.05B
Update: 2025-11-17
Description
Johnson and Johnson bolsters its oncology portfolio with Halda Therapeutics acquisition, focusing on prostate cancer and other solid tumors.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel




